Clearmind Medicine (CMND) shares surged more than 84% premarket Tuesday after the company said it has received Institutional Review Board approval from Yale University for the phase 1/2a clinical trial of CMND-100 in alcohol use disorder.
The company said the approval brings it a step closer to starting the US Food and Drug Administration-regulated clinical program and further expands the multi-site trial.
According to Clearmind Medicine, the trial is designed to evaluate CMND-100's ability to reduce alcohol cravings and consumption among individuals with moderate to severe alcohol use disorder.
Price: 2.25, Change: +1.03, Percent Change: +84.43
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。